Program
EMB-15
A development code.
Its studies are led by Shanghai EpimAb Biotherapeutics.
Furthest: phase 1, since May 19, 20261 company-led study, 1 open or runningNext primary completion: May 31, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai EpimAb Biotherapeutics | 11 open or running | phase 1since May 19, 2026 | May 19, 2026 | May 31, 2029phase 1 · NCT07607054 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2026First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT07607054 · 50 planned · China
Ahead
- May 31, 2029Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT07607054
TargetBeta
“EMB-15 is a recombinant humanized bi-specific antibody against ALPP/ALPG and CD3”study text, by rule · the study
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07607054Locally Advanced or Metastatic Solid Tumors · China | 1 | Recruiting | May 31, 2029 | 50 |
How it is read
Names in the registry
- “EMB-15”, 1 entry
Codes read as this program: EMB15.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.